Skip to main content
Dryad

Adaptive, randomized, non-inferiority trial to evaluate the efficacy of monoclonal antibodies in outpatients with mild or moderate COVID-19

Data files

Nov 15, 2022 version files 677.96 KB

Abstract

The dataset is based on the results of a trial called MANTICO (Clinical trial number NCT05205759). The study is a non-inferiority randomised controlled trial comparing the clinical efficacy of bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab in outpatients aged 50 or older with early COVID-19. The primary outcome was COVID-19 progression (hospitalisation, need of supplemental oxygen therapy, or death through day 14).